DrugPatentWatch Database Preview
Drugs in Development Information for Gimeracil
» See Plans and Pricing
What is the drug development status for Gimeracil?
Gimeracil is an investigational drug.
There have been 67 clinical trials for Gimeracil.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Quintiles, Inc.
There are one hundred and twenty-seven US patents protecting this investigational drug and nine hundred and ninety-eight international patents.
Summary for Gimeracil
| US Patents | 127 |
| International Patents | 998 |
| US Patent Applications | 202 |
| WIPO Patent Applications | 929 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2013-06-01) |
| Vendors | 95 |
Recent Clinical Trials for Gimeracil
| Title | Sponsor | Phase |
|---|---|---|
| A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | Lee's Pharmaceutical Limited | Phase 2 |
| Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) | Yu jiren | Phase 2 |
| Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer | ACT Genomics | Phase 2 |
Clinical Trial Summary for Gimeracil
Top disease conditions for Gimeracil
Top clinical trial sponsors for Gimeracil
US Patents for Gimeracil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gimeracil | Start Trial | Metal-salen complex compound, local anesthetic and antineoplastic drug | IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP) | Start Trial |
| Gimeracil | Start Trial | Multimodal silica-based nanoparticles | Start Trial | |
| Gimeracil | Start Trial | Device and method for drug evaluation and local treatment | Kibur Medical, Inc. (Boston, MA) | Start Trial |
| Gimeracil | Start Trial | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | STC.UNM (Albuquerque, NM) | Start Trial |
| Gimeracil | Start Trial | Pharmaceutical compositions comprising POH derivatives | NeOnc Technologies, inc. (Los Angeles, CA) | Start Trial |
| Gimeracil | Start Trial | Medical device for analyte monitoring and drug delivery | Theranos, IP Company, LLC (Palo Alto, CA) | Start Trial |
| Gimeracil | Start Trial | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | CanBas Co., Ltd. (Numazu, JP) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gimeracil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gimeracil | China | CN103781760 | 2031-06-13 | Start Trial |
| Gimeracil | European Patent Office | EP2738158 | 2031-06-13 | Start Trial |
| Gimeracil | Japan | JP2013001646 | 2031-06-13 | Start Trial |
| Gimeracil | Japan | JP5873656 | 2031-06-13 | Start Trial |
| Gimeracil | Russian Federation | RU2013156414 | 2031-06-13 | Start Trial |
| Gimeracil | Russian Federation | RU2617450 | 2031-06-13 | Start Trial |
| Gimeracil | World Intellectual Property Organization (WIPO) | WO2012172892 | 2031-06-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
